Amedisys Ownership
| AMED Stock | USD 97.71 0.25 0.26% |
Shares in Circulation | First Issued 1993-03-31 | Previous Quarter 32.7 M | Current Value 33.2 M | Avarage Shares Outstanding 21.6 M | Quarterly Volatility 12.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. Amedisys Stock Ownership Analysis
About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Amedisys was presently reported as 36.55. The company has Price/Earnings To Growth (PEG) ratio of 1.42. Amedisys had not issued any dividends in recent years. The entity had 4:3 split on the 5th of December 2006. Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 21000 people. For more info on Amedisys please contact Richard Ashworth at 225 292 2031 or go to https://www.amedisys.com.Besides selling stocks to institutional investors, Amedisys also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Amedisys' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Amedisys' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Amedisys Quarterly Liabilities And Stockholders Equity |
|
Amedisys Insider Trades History
Only 1.96% of Amedisys are currently held by insiders. Unlike Amedisys' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Amedisys' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Amedisys' insider trades
Amedisys Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amedisys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amedisys backward and forwards among themselves. Amedisys' institutional investor refers to the entity that pools money to purchase Amedisys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-03-31 | 634.5 K | Qube Research & Technologies | 2025-03-31 | 621.1 K | Bank Of America Corp | 2025-03-31 | 606.2 K | Millennium Management Llc | 2025-03-31 | 605.6 K | Geode Capital Management, Llc | 2025-03-31 | 599.9 K | Balyasny Asset Management Llc | 2025-03-31 | 587.3 K | Cnh Partners, Llc | 2025-03-31 | 577.5 K | Water Island Capital Llc | 2025-03-31 | 558.4 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 509.3 K | Blackrock Inc | 2025-03-31 | 3.3 M | Vanguard Group Inc | 2025-03-31 | 3.2 M |
Amedisys Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amedisys insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amedisys Outstanding Bonds
Amedisys issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Amedisys uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Amedisys bonds can be classified according to their maturity, which is the date when Amedisys has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AMCR 3625 28 APR 26 Corp BondUS02343UAG04 | View | |
| AMCR 45 15 MAY 28 Corp BondUS02343UAH86 | View | |
| AMCR 269 25 MAY 31 Corp BondUS02344AAA60 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| DOX 2538 15 JUN 30 Corp BondUS02342TAE91 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Amedisys Corporate Filings
F4 | 7th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 1st of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 29th of April 2025 An amendment to a previously filed Form 10-K | ViewVerify |
10Q | 24th of April 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.182 | Earnings Share 2.72 | Revenue Per Share | Quarterly Revenue Growth 0.041 | Return On Assets |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.